Ketone Monitoring Approaches for DKA Risk Mitigation in People with T1D on Adjunctive SGLT2 Inhibitors (KARMA) - Abstract People with type 1 diabetes (T1D) are at increased risk of cardiovascular disease (CVD), heart failure (HF) and chronic kidney disease (CKD). SGLT2 inhibitors have been shown to decrease risk of CVD, HF, and to slow the progression of CKD in people with Type 2 diabetes. However, the FDA has not approved the use of SGLT2 inhibitors as adjunctive treatments for T1D because of a ~6-fold increase in the risk of diabetic ketoacidosis (DKA). In trials of SGLT2 inhibitors in people with T1D, self-monitored plasma beta-hydroxybutyrate (BOHB) levels were predictive of DKA but this type of monitoring did not prevent ketoacidosis. Recent advances have enabled continuous monitoring of BOHB levels in interstitial fluid – raising the possibility that continuous ketone monitoring (CKM) could effectively mitigate the increased risk of DKA in SGLT2 inhibitor treated patients with T1D. The overarching goal of this proposal is to develop and test a pragmatic risk mitigation strategy using CKM that will enable safer use of SGLT2 inhibitors in patients with T1D. To accomplish this, we will recruit and study a diverse cohort of 75 patients with T1D to address 3 Specific Aims. In Aim 1a we will determine how adjunctive SGLT2 inhibitor use affects the development of hyperglycemia, ketosis and ketoacidosis during insulin withdrawal testing (IWT) in a highly controlled, inpatient setting in people with T1D on insulin monotherapy to that on insulin + adjunctive therapy with an SGLT2 inhibitor. In Aim 1b we will assess insulin, carbohydrate and fluid requirements to reverse ketosis during these conditions to refine recovery protocols that reverse elevated ketones during these conditions. We hypothesize that adjunctive SGLT2 inhibitor use will increase the rate of development and maximal levels of ketosis and ketoacidosis while blunting increases in glucose during an insulin withdrawal test. In Aim 2a we will test the effectiveness of a CKM enabled DKA risk mitigation strategy that accounts for the increased risk for ketosis and ketoacidosis with SGLT2 inhibitors. We will use a sequential, 2- phase study design to compare the number and severity of CKM-assessed ketone events that occur during a generalized DKA risk mitigation plan vs. a personalized DKA plan implemented for people with T1D on SGLT2 inhibitors. In Aim 2b we will actively update ‘decision tree algorithms’ for broad risk mitigation to incorporate new learnings obtained during the conduct of the study using an adaptive design. We hypothesize that a strategy accounting for the physiological effects of SGLT2 inhibitors on the development and resolution of ketosis will be more effective at reducing the number and severity of ketosis events. In Aim 3 we will explore intrinsic and extrinsic factors associated with ketone levels and responses to SGLT2 inhibition among people with T1D in both free living conditions and during IWT by conducting secondary analyses of data generated in Aims 1 and 2 to determine possible predictors of the number and severity of ketone events and responses to SGLT2 inhibition. The results of this study will lead to an improved risk mitigation strategy that will enable persons with T1D to safely use SGLT2 inhibitors to decrease risk for CVD, HF and CKD, thus improving long-term outcomes.
